Should We Consider Aging a Disease?


Canva

In 1851, blacks throughout the US were reported to suffer from a disease called “drapetomania.” The symptoms—a white physician argued—were bouts of “sulkiness,” followed by an inexplicable urge to flee plantations. The treatment, he wrote, was to have “the submissive kneebender (which the Almighty declared [‘the negro’] should be)” relatively “well fed and clothed,” occasionally “whipping them,” to “cure them from running away.”

For better or worse, no definition of disease exists independent of historical context. In 2022, an infertile woman may be said to possess a medical condition. In the 1600s, the same woman may have been burned at the stake, or said to bear “a wandering womb” (as medieval concepts of anatomy included “the womb being able to run around inside the body at will”). In 2065, still the same woman may be considered perfectly healthy, if childbearing becomes the job of artificial wombs.

This notion—that the term “disease” is not static—complicates the moral distinction between “therapy” and “enhancement.” Some bioethicists argue that therapies should be pursued which prevent human suffering. Yet human suffering does not fall categorically outside the boundaries of early-21st-century conceptions of health. In 2022, one can both suffer and be considered healthy—or, as one definition of the absence of disease suggests, one can be on “the normal functioning path of the organism.”

If a person lives to be 100 years old, they are almost certain to develop cancer. Indeed, 96 percent of all cancers occur in patients aged 35 and older. This means that cancers are often not a deviation from “the normal functioning path of the organism”—and yet we treat them as abnormal. Human aging is not yet widely considered a disease, but can be perceived as the primary cause of suffering in our century. Scientifically, aging can be understood as the source of all the leading causes of death in 2022, including COVID-19—around 90 percent of all US deaths from the virus were patients over 60.

Economically, the gradual decay of our unprecedentedly long-lived populations costs the US nearly half its federal budget every year. It’s no wonder that the most well-funded pre-seed biotechnology startup in history—Altos Labs, which boasts an impressive list of Nobel laureates and enjoys funding from Jeff Bezos—is committed to the idea that aging, even if normal to our species, is also profoundly harmful. It’s unsurprising, too, that the Saudi royal family is planning to donate a billion dollars a year to aging science.

A growing number of scientists suggest that aging is the (treatable) disease of which most cases of Alzheimer’s, heart disease, and cancer are symptoms. Over the past century, we engineered more than a doubling in average life expectancy, but average health-span has hardly changed throughout the history of humankind.

Aging therapies are often deemed superfluous because, through the myopic lens of early-21st-century morality, they constitute “enhancement”: a deviation from the sick-care model of therapeutics whereby diseases are only named—and treated—retroactively.

Is aging an essential part of our design?

Today, human aging and being human are often conflated as a single process, aging being comprehended as a mystico-teleological phenomenon designed by tenderhearted gods to furnish human life with meaning. When cancers were first documented in ancient Egypt, they were similarly thought to be a product of celestial ingenuity: as the American Cancer Society writes, “Ancient Egyptians blamed cancers on the gods”—but their theology was consistent with this proposition.

In 2022, if we choose to accept post-Enlightenment evolutionism, reality is far more grim: when it comes to longevity, as David A. Sinclair writes in Lifespan, “individuals look out for themselves.” We have been painfully slow to revise Aristotle’s unscientific—and highly influential—theory that older adults die to make way for the young. Now, several biologists dispute the notion that aging and its ailments exist for a reason special to us. They reject the belief that what Yuval Harari has called “the human spark” could ensure biological processes exist to advance human ideals.

Humans, unlike other primates, have a fondness for mythological narratives of grandeur and heroism—often, at the expense of comprehending the more humdrum or capricious reasons for why things happen. Cancers, like the processes of aging, constitute not one, but several diseases. They develop not so civilizations may prosper and flourish, but as happenstance features of haphazardly conceived systems. Biologically immortal species (like the jellyfish Turritopsis dohrnii) offer good evidence that aging is not inevitably beneficial to life, and may well be considered a multifactorial genetic disease, the universality of which in humans makes it more—not less—harmful.

Concerns that this shift may provoke ageism ought to be addressed by preventing older (not younger) individuals from enjoying excessive perks, such as holding onto a job for 80 years. And even if calling aging a disease is a conflation of cause and effect, language only works because it allows for such imperfect generalizations, with far-reaching effects in the real world.

In The Blank Slate, Steven Pinker reminded us that natural selection is “morally indifferent”: no engineer is tasked with guaranteeing that the survival of specific genes aligns with human aspirations. To think, as the philosopher Hans Jonas does, of “the organically programmed dying of parent generations to make room for their offspring” is to subscribe to the gawky mishmash of a creationist-secularist view—accepting the callousness of a godless universe, while hoping, still, for teleological protection from our designer-gods.

Absent effective aging drugs, one of humanity’s most pressing problems by the year 2100 will be the contraction of the global population. Without young immigrants, the United States would already be experiencing negative growth, and Japan is set to lose 21 million people by 2050.

The current global population of nearly eight billion people (better fed and sheltered than at any time in human history) is proof that large populations in themselves are not the problem. Indeed, as Peter Diamandis and Steven Kotler argue in The Future Is Faster Than You Think, an unprecedented number of well-nourished minds working towards human flourishing is what made feats like the Enlightenment possible.

But, to most early-21st-century humans, there remains something deeply unsettling about the treatment of human bodies as high-tech mechanical devices to be tweaked. Should we be striving for this kind of limitless “enhancement”? Could human life be purchased, like silicon devices? What about our very special spark?

When we discard teleological narratives of almighty gods—which in the past (as in 1851) served as heuristics for profoundly irrational and immoral deeds—the facts become clear. If evolution had our flourishing in mind when it produced the processes of aging millions of years ago, this benefit is no longer valid. And if we choose to treat Alzheimer’s or fund retirement programs, then the preventative treatment of the fundamental processes of aging is not simply a pet-project for future, more stable civilizations, but an ethical imperative if civilizations wish to become more stable.

Who will receive treatment?

Today’s aging therapies are far from equitably distributed. Those with some arguable benefits—including NMNs and metformin—even when offered at a low cost, remain unsought by lower-income populations due to systemic barriers. Further, governments rarely fund fundamental aging research (only 0.54 percent of all National Institutes of Health funding is devoted to it), which delays at once the democratization of existing therapies and the advancement of clinical safety studies for more effective ones.

But just as safe and affordable cancer treatments are not yet here, and champions of a cure for cancer are untrained in the science and economics of promising drugs, so too, one need not agree on the nuances of aging therapies to find their potential success—including safety and affordability—ethically permissible.

As Sinclair writes, “effective longevity drugs will cost pennies on the dollar compared to the cost of treating the diseases they will prevent.” If we decide to name the fundamental processes of aging a disease, governments and average individuals would incur fewer costs, freeing up capital for other important human aspirations, such as wider access to medical therapies.

Yes, Jeff Bezos, Mark Zuckerberg, and Peter Thiel stand to make vast profits from the sale of human life and health. And yes, they are sure to benefit from aging therapies far sooner than my family in rural Brazil. But if their funding can advance these therapies towards clinical safety, helping to save billions of lives while unburdening our healthcare systems, this would be a just distribution of capital-for-output.

In the end, it’s up to us whether or not we think of aging as an essential part of the human condition. Science, we must remind ourselves, advances not one funeral, but one hard-working, living human at a time. There is hardly a belief more harmful than that biological decay is a mystical, kind, or dialectical force, guiding humanity towards its predetermined and unalterable telos.

It is human agency—with the sweat, faults, and capriciousness of the living—that engenders progress. It is our own ever-ungainly understanding of terms like “disease” and “health” that designs the future of our species.

By: Raiany Romanni

Raiany Romanni is a Harvard Kennedy Fellow in Effective Altruism, A360 Scholar, VitaDAO Fellow, ODLB2, and bioethicist.

Source: Should We Consider Aging a Disease?

Related contents:

Marketing Programs You May Like:

10 Bold Actions In Positive Life     https://jvz3.com/c/202927/383942/
3D Pal Toons     https://jvz6.com/c/202927/381689/
4brandcommercial        https://jvz1.com/c/202927/375487
7 Minutes Kit      https://jvz8.com/c/202927/374505/
9 figure Success        https://jvz8.com/c/202927/384653/
Ad Raven      https://jvz4.com/c/202927/382796/
ADA Bundle   https://jvz6.com/c/202927/389298/
Ada leadz     https://jvz8.com/c/202927/376381
ADA Web      https://jvz3.com/c/202927/383751/
AdRaven       https://jvz3.com/c/202927/382851/
Adsense Machine      https://jvz2.com/c/202927/290487
Adtivate Agency      https://jvz3.com/c/202927/383700/
AdvertSuite     https://jvz1.com/c/202927/335011/
AdzHero     https://jvz2.com/c/202927/366972/
AffiliateMatic     https://jvz3.com/c/202927/381148/
Agency Client Finder    https://jvz3.com/c/202927/384619/
AgencyScale      https://jvz4.com/c/202927/383111/
AIWA Commercial     https://jvz2.com/c/202927/365061
ALL-in-One HD Stock    https://jvz4.com/c/202927/381560
Animaxime    https://jvz2.com/c/202927/383307/
Appimize      https://jvz8.com/c/202927/370227
Appoint B Agency     https://jvz1.com/c/202927/384630/
Appointomatic      https://jvz6.com/c/202927/374258
Appowls    https://jvz4.com/c/202927/381231/
Art Of Living    https://jvz4.com/c/202927/382425/
Audiencetoolkit     https://jvz6.com/c/202927/302715
Audio Studio  https://jvz8.com/c/202927/389119/
Aweber Crash Course     https://jvz6.com/c/202927/383057/
Backlinkindexer    https://jvz6.com/c/202927/88118
BettingMaster      https://jvz2.com/c/202927/387079/
BevTraders    http://www.bevtraders.com/?ref=arminham
Big Audio Club     https://jvz6.com/c/202927/380087/
BigAudio Club    https://jvz2.com/c/202927/380877/
Boost Optimism   https://jvz2.com/c/202927/380692/
BrandElevate   https://jvz4.com/c/202927/381807/
BrandElevate   https://jvzoo.com/c/202927/381812
Bybit     https://www.bybit.com/en-US/invite?ref=ALEXP
CanvaKitz    https://jvz4.com/c/202927/379051/
ChatterPal    https://jvz8.com/c/202927/324615
Clientfinda   https://jvz8.com/c/202927/370806
Clipsreel   https://jvz3.com/c/202927/372682
Commission smasher   https://jvz3.com/c/202927/376879
Content Gorilla   https://jvz2.com/c/202927/330783
Content Tool Kit   https://jvz3.com/c/202927/329145/
contentGenie   https://jvz4.com/c/202927/387717/
CourseAlly eLearning   https://jvz4.com/c/202927/384759/
CourseReel   https://jvz2.com/c/202927/355249
Courserious   https://jvz8.com/c/202927/360397/
Coursova   https://jvz1.com/c/202927/376527
Creaitecontent  https://jvz1.com/c/202927/376986
Credit Repair   https://jvz8.com/c/202927/377815/
Cryptokit    https://jvz8.com/c/202927/383809/
CryptoRocket    https://jvz6.com/c/202927/378113/
CryptoUnderworld     https://jvz8.com/c/202927/374345/
Dealcheck     https://dealcheck.io?fp_ref=armin16
DesignaSuite      https://jvz2.com/c/202927/297271
DesignBeast    https://jvz6.com/c/202927/371547
DevelopSelfEmpowerment     https://jvz6.com/c/202927/383094/
DFYContentClub     https://jvz6.com/c/202927/381337/
DFYSuite   https://jvz3.com/c/202927/381194/
Diabetes Guide    https://jvz2.com/c/202927/358870/
Diddly Pay’s    https://jvz2.com/c/202927/315596
Diet fitness diabetes   https://jvz1.com/c/202927/286851
Domainname    https://jvz6.com/c/202927/377005
Dominate Email   https://jvz4.com/c/202927/386980/
Doodleoz   https://jvz8.com/c/202927/388700/
Dropshiply   https://jvz3.com/c/202927/383483/
DUX Forex Signals   https://jvz3.com/c/202927/128215/
EBook Agency    https://jvz2.com/c/202927/384573/
Ejaculation Total   https://jvz2.com/c/202927/75989/
Email Monetizer    https://jvz2.com/c/202927/386337/
EngagerMate  https://jvz8.com/c/202927/328172
EngageYard   https://jvz2.com/c/202927/383051/
Explaindio    https://jvz1.com/c/202927/123757/
Extreme Adz   https://jvz8.com/c/202927/379244/
Extreme Coupon  https://jvz1.com/c/202927/216101/
EZ Local Appointment  https://jvz2.com/c/202927/385180/
EZDeals  https://jvz8.com/c/202927/377689/
Ezy  https://jvz1.com/c/202927/381935/
Ezy MultiStores  https://jvzoo.com/c/202927/381935
Facebook Cash Machine   https://jvz4.com/c/202927/382333/
Facedrip  https://jvz1.com/c/202927/376325/
FaceSwap   https://jvz4.com/c/202927/381768/
Fade To Black   https://jvz2.com/c/202927/344541
Fanpage  https://jvz4.com/c/202927/144349
Fitness Nutrition   https://jvz4.com/c/202927/353334/
Followup Builder   https://jvz3.com/c/202927/386313/
Forex Atlatian   https://jvz8.com/c/202927/25069/
Forex Blizz   https://jvz8.com/c/202927/144577/
Forex Blue Stark  https://jvz3.com/c/202927/47481/
Forex expert   https://jvz1.com/c/202927/376877
Forex Hybrid Scalper    https://jvz6.com/c/202927/95037/
Forex Joustar   https://jvz6.com/c/202927/381617/
Forex Mastery   https://jvz2.com/c/202927/144621/
Forex Scouts   https://jvz6.com/c/202927/132677/
forrk  https://jvz1.com/c/202927/373449
FusionMT4    https://jvz2.com/c/202927/372523/
FX Goldminer  https://jvz1.com/c/202927/381439/
Galactic  https://jvz1.com/c/202927/188236/
Gaming job   https://jvz2.com/c/202927/184902  s
Genesis Mining   https://www.genesis-mining.com/a/2535466
Gluten free   https://jvz4.com/c/202927/296191
GMB Snap  https://jvz4.com/c/202927/376661/
Graphic Alta  https://jvz2.com/c/202927/324492/
Heal Your Emptiness   https://jvz6.com/c/202927/384848/
High Converting Emails  https://jvz3.com/c/202927/386305/
HostLegends    https://jvz4.com/c/202927/384774/
Hostley Domain Creator   https://jvz1.com/c/202927/379223/
Human Synthesys Studio  https://jvz8.com/c/202927/367353/
ImageX   https://jvz6.com/c/202927/363237/
IMSyndicator  https://jvz1.com/c/202927/370769
Inboxr   https://jvz2.com/c/202927/312692
Insta Keyword    https://jvz6.com/c/202927/351606/
Instant Website   https://jvz2.com/c/202927/377557
InstantWebsiteBundle          https://jvz6.com/c/202927/377557
iTraffic X  https://jvz2.com/c/202927/320466
keysearch  https://jvz4.com/c/202927/236407/
KlickCourse   https://jvz3.com/c/202927/385006/
KlickXCopy    https://jvz3.com/c/202927/385458/
Klippyo Kreators  https://jvz8.com/c/202927/327447
KoinCart   https://jvz2.com/c/202927/383555/
Leadvalet   https://jvz3.com/c/202927/385580/
LegalSuites   https://jvz2.com/c/202927/388896/
Levidio Royal Podcasting   https://jvz6.com/c/202927/384025/
Linkable DFY   https://jvz6.com/c/202927/385873/
Linkomatic  https://jvz2.com/c/202927/380937/
LiteTrading   https://www.litefinance.com/?uid=929237543
Live Your Truth  https://jvz6.com/c/202927/379020
Living An Intentional Life    https://jvzoo.com/c/202927/382455
Living an International Life    https://jvz8.com/c/202927/382455/
Local Leader   https://jvz4.com/c/202927/383751/
Local Sites   https://jvz4.com/c/202927/380543/
LocalAgencyBox  https://jvz2.com/c/202927/359468
LocalCentric   https://jvz2.com/c/202927/379339/
LocalioAI    https://jvz6.com/c/202927/378310/
MarketAll      https://jvz2.com/c/202927/386971/
Marketingblocks     https://jvz6.com/c/202927/374934
MarketPresso   https://jvz2.com/c/202927/369837
Massfluence  https://jvz4.com/c/202927/386885/
Mat1 Simple Funnel   https://jvz2.com/c/202927/380197/
Maxslides  https://jvz8.com/c/202927/376842
Mech Forex Robot   https://jvz6.com/c/202927/383447/
MediaCloudPro   https://jvz2.com/c/202927/343635
Megasuite   https://jvz3.com/c/202927/383953/
Mobi First   https://jvz2.com/c/202927/353694/
Motion Kingdom Studio  https://jvz4.com/c/202927/383177/
Movid Animation  https://jvz6.com/c/202927/380385/
MT4Code System   https://jvz2.com/c/202927/376925
My Passive Income   https://jvz1.com/c/202927/384099/
MyMailIt   https://jvz3.com/c/202927/292919
MyTrafficJacker   https://jvz2.com/c/202927/353558
Next Drive  https://jvz4.com/c/202927/371095/
NichBox  https://jvz2.com/c/202927/370705/
Organic Life Guide  https://jvz8.com/c/202927/366872/
Pcommerce   https://jvz6.com/c/202927/372265/
Phemex  https://phemex.com/register-vt1?referralCode=D8HUS2
Photokit  https://jvz4.com/c/202927/373207/
PicsAds   https://jvz2.com/c/202927/385468/
PigMoneyMethod   https://jvz2.com/c/202927/377665/
Pipstock    http://pipstockexchange.com/register?ref=204
Pitchdeck   https://jvz3.com/c/202927/347847/
Pixal  https://jvz2.com/c/202927/378775/
PixaStudio    https://jvz1.com/c/202927/373089/
Pixivid   https://jvz6.com/c/202927/385213/
PlanB Muscle Growth   https://jvz1.com/c/202927/36517/
PlayerNeos   https://jvz2.com/c/202927/376962
Podcast Advantage   https://jvz8.com/c/202927/379995/
Podcast Masterclass  https://jvz3.com/c/202927/379998/
PodKastr    https://jvz1.com/c/202927/369500/
PopLinks    https://jvz2.com/c/202927/368095/
Postradamus     https://jvz6.com/c/202927/108695
Power Reviews    https://jvz8.com/c/202927/384625/
Powrsuite   https://jvz1.com/c/202927/376361
PR Rage  https://jvz4.com/c/202927/343405
Prime Stocks   https://jvz8.com/c/202927/369164
Profile mate    https://jvz4.com/c/202927/358049
Promovidz   https://jvz8.com/c/202927/375692/
Push Button Traffic   https://jvz2.com/c/202927/301402
PWA Agency   https://jvz1.com/c/202927/353694/
QR Verse   https://jvz3.com/c/202927/383865/
Quintex Capital     https://quintexcapital.com/?ref=arminham
Quit Smoking    https://jvz3.com/c/202927/359081/
QuizMatic   https://jvz6.com/c/202927/387116/
Reputor   https://jvz8.com/c/202927/380159/
ReVideo  https://jvzoo.com/c/202927/381761
ReviewReel   https://jvz6.com/c/202927/382663/
Rewriter   https://jvz4.com/c/202927/353373/
RSI SEO   https://jvz6.com/c/202927/384381/
Scriptdio   https://jvz4.com/c/202927/385387/
Self Validation   https://jvz6.com/c/202927/389174/
Sendiio   https://jvz3.com/c/202927/325450/
Seniors Income    https://jvz2.com/c/202927/383888/
Senuke  https://jvz6.com/c/202927/279944
ShopABot   https://jvz2.com/c/202927/291955
ShopFunnels   https://jvz3.com/c/202927/384069/
SocialAgency360   https://jvz1.com/c/202927/385357/
SocialMediaMarketing   https://jvz2.com/c/202927/243553/
SociCake  https://jvz2.com/c/202927/321987
Socifeed   https://jvz6.com/c/202927/375706
SociJam  https://jvz2.com/c/202927/309649
Soronity  https://jvz6.com/c/202927/368736
SqribbleEbook   https://jvz6.com/c/202927/283867
Stackable Picture   https://jvz1.com/c/202927/385046/
Steven Alvey’s   https://jvz2.com/c/202927/351754
Stock Mages   https://jvz2.com/c/202927/388669/
Stoodaio   https://jvz1.com/c/202927/372094
Storymate    https://jvz3.com/c/202927/320972
StoryReel   https://jvz3.com/c/202927/387813/
StreamPilot   https://jvz2.com/c/202927/385431/
Studioninja   https://jvz1.com/c/202927/374965
Sunday Freebie  https://jvz1.com/c/202927/267113/
Super backdrop   https://jvz8.com/c/202927/376524
Survai    https://jvz8.com/c/202927/380933/
Syndranker    https://jvz3.com/c/202927/378143/
Talkingfaces   https://jvz3.com/c/202927/375550
The Internet Marketing   https://jvz2.com/c/202927/289944
Tonai Voice Content   https://jvz8.com/c/202927/383119/
Toon Video Maker    https://jvz2.com/c/202927/357201
TrafficForU   https://jvz3.com/c/202927/381950/
Trendio  https://jvz3.com/c/202927/381003/
TubePal   https://jvz6.com/c/202927/379863/
Tubeserp   https://jvz3.com/c/202927/370472
TubeTargeter  https://jvz6.com/c/202927/377211
TuneMingo    https://jvz3.com/c/202927/386556/
TV Boss Fire  https://jvz6.com/c/202927/379480/
Ultrafunnels A.I   https://jvz2.com/c/202927/381129/
VIADZ Ad Template  https://jvz4.com/c/202927/379307/
Vidcentric   https://jvz4.com/c/202927/376095
Viddeyo    https://jvz6.com/c/202927/382326/
Videevolve   https://jvz4.com/c/202927/381011/
Vidently   https://jvz1.com/c/202927/387798/
Video Campaignor      https://jvz4.com/c/202927/387058/
Video Games   https://jvz3.com/c/202927/184902/
VideoEnginePro     https://jvz2.com/c/202927/372916
VideoGameSuite    https://jvz3.com/c/202927/366537/
VideoRobot Enterprise   https://jvz8.com/c/202927/291061
VidKreate   https://jvz6.com/c/202927/386029/
VidMingo   https://jvz6.com/c/202927/378359/
VidRaffle   https://jvz2.com/c/202927/386840/
VidSnatcher    https://jvz3.com/c/202927/342585
VidVoicer    https://jvz1.com/c/202927/379983/
Vidzura   https://jvz4.com/c/202927/385754/
Viral dash   https://jvz6.com/c/202927/375959
Viral Quotes      https://jvz2.com/c/202927/386984/
VirtualReel   https://jvz8.com/c/202927/376849
Vocalic  https://jvz2.com/c/202927/383848/
VoiceBuddy    https://jvz1.com/c/202927/342854
VR Studio  https://jvz8.com/c/202927/388296/
WebCop  https://jvz4.com/c/202927/378683/
Webinarkit   https://jvz3.com/c/202927/383937/
Webprimo   https://jvz1.com/c/202927/379455/
WordPress Mastery   https://jvz1.com/c/202927/386249/
WowBackgraounds   https://jvz2.com/c/202927/381556/
WP GDPR    https://jvz8.com/c/202927/299907
WP Simulator    https://jvz3.com/c/202927/46987/
Writer Arc   https://jvz1.com/c/202927/386602/
writing job   https://jvz8.com/c/202927/213027
XBrain Forex   https://jvz3.com/c/202927/372305/
XFUNNELS   https://jvz2.com/c/202927/310335
Xinemax  https://jvz1.com/c/202927/381749/
YoDrive   https://jvz2.com/c/202927/384700/
YoSeller   https://jvz4.com/c/202927/387544/
Your 3DPal   https://jvz2.com/c/202927/381685/
YTSuite   https://jvzoo.com/c/202927/381179
Zappable   https://jvz3.com/c/202927/367328/

At-Home Covid Tests Are Getting Better

As many of us rush around trying to find the perfect Thanksgiving turkey and holiday gifts, there’s another thing experts recommend we stock up on: at-home tests for Covid-19.

“At-home testing will be essential over the next few months,” said Leana Wen, an emergency physician and professor of health policy at George Washington University.

The most common form of at-home testing is the rapid antigen test — think BinaxNOW, QuickVue, or Ellume — where you swab your own nostrils and get results back in around 15 minutes. These can be found at your local pharmacy, though supply has been erratic (more on this below). Antigen tests are typically contrasted with molecular tests — think lab-based PCR — which are better at picking up the virus, though you have to get swabbed by a professional and then wait, sometimes several days, until results come back.

Now, however, companies like Cue Health and Detect are selling a new class of tests: molecular tests that can be performed entirely at home. They promise PCR-quality results in under an hour — all without ever having to get up off your couch.

If you can find and afford at-home tests — whether they’re the relatively cheap antigen tests or their more expensive molecular cousins — experts say it will be particularly useful for you to have them on hand this fall and winter, for a few reasons.

For Americans who got their first two doses this spring, immunity may well be waning. Data so far shows the vaccines’ effectiveness against infection tapers off around the six-month mark. And so far, only 18 percent of Americans have gotten a booster shot (though that may well rise now that all adults are eligible). That, together with the fact that infection rates are climbing in the US, means breakthrough cases are likely to rise here, as they’ve already begun to do in Europe. And with the weather getting colder and the holidays coming, we’re all going to be spending more time indoors with others.

To be clear, if you’re fully vaccinated, the data shows you’re still well protected from severe disease or death from Covid-19, and reported infections in the US are so far still mainly among unvaccinated people. But should you get a breakthrough infection, you could infect others who are unvaccinated, have waning immunity, or are elderly and thus more at risk for severe illness even if they are vaccinated. That’s what testing can prevent.

“We need to shift from thinking about at-home testing as just a diagnostic tool to thinking about it as a preventative tool,” said Wen, who recommends taking a test before an indoor social gathering even if you’re not feeling symptoms.

Neil Sehgal, a health policy professor at the University of Maryland School of Public Health, told me he’s about to fly from Washington, DC, to California to spend Thanksgiving with relatives there. Everyone in his family plans to take a rapid test before the holiday meal, he said, to help ensure they don’t pose a risk to others.

“The challenge right now is that even if you are vaccinated, your breakthrough infection is a link in a chain that may end up infecting somebody for whom consequences may be more serious than for you,” Sehgal told me. “We all have to make a decision about whether or not we want to participate in those chains of transmission.”

Likewise, Wen said she’s planning to use rapid tests for holiday get-togethers. She also finds them useful for birthday parties and dinner parties; now that it’s getting too cold for outdoor meals, her family and her invited guests test before gathering in her home.

Both experts noted that there’s an additional reason why it’s useful to keep a few tests in your house in the coming months: Antiviral pills for Covid-19, produced by Merck and Pfizer, will probably soon be available in the US under an emergency use authorization. But these treatments are most effective if you take them soon after you’ve become infected. That means it’s in your interest to catch the virus early on — and having a test close to hand can help you do that.

It shouldn’t be so hard to get at-home tests. Here’s what went wrong.

One issue clouds these expert recommendations: The availability of at-home test kits has been spotty at best.

An American, looking at how easy it is to snag a rapid test across the pond in the UK or Germany, could be forgiven for feeling a pang of envy — and a hefty dose of frustration. More than a year and a half into the pandemic, over-the-counter antigen tests are often sold out at stores like CVS or Walgreens.

Despite the Biden administration’s decision to invest $1 billion in rapid tests, the market remains constrained, in part because of regulatory hurdles. Early on, the US decided to categorize these tests as medical devices, which means they needed to pass a stringent FDA approval process, Sehgal explained. As a result, only a few companies’ tests squeezed through to market in 2021.

“We’ve been slow to adopt and approve them in the US because they’re not as sensitive as PCR tests,” Sehgal said. But even though antigen tests are not foolproof at detecting the virus, “they are sensitive enough to give you a pretty realistic sense of whether you pose a risk to the people you’re gathering with” — that is, of whether you’re actively contagious.

“I do think a more public-health-minded mental model would have led to quicker approval of more rapid antigen testing options,” Sehgal continued. In other words, the US should have conceived of the tests as a harm reduction measure: We know they’re not perfect, but if we deploy them at scale, they’ll reduce harm overall.

“The FDA would still have to approve them under an emergency use authorization to make it to market, but the urgency with which the FDA has acted with vaccines could have been similarly applied to testing. If so, I think we’d have seen earlier approvals for more domestic manufacturers of rapid tests,” he added.

Another reason for the low stock is simply that bigger purchasers snapped up a lot of the tests early on. Companies, sports teams, and school systems placed bulk orders in the spring and ate up a lot of the stock before the general public could get to it. “They made contracts because they knew that to resume in-person activity, this would be a good strategy,” Sehgal said.

The upshot is that when regular individuals walk into their drugstores to try and buy a couple boxes, there’s not much left on the shelf.

Under the Trump administration, officials at times appeared to discourage testing, for fear that it would reveal more positive cases. Instead, the US focused on developing vaccines at warp speed, thinking of them as the silver bullet that would destroy the pandemic.

But this fall, the Biden administration decided to make testing a more integral part of its pandemic strategy. White House coronavirus response coordinator Jeff Zients said in October that the $1 billion investment “puts us on track to quadruple the amount of at-home, rapid tests available for Americans by December. So that means we’ll have available supply of 200 million rapid, at-home tests per month starting in December.”

Many experts hailed it as a welcome, if overdue, commitment.

“What rapid tests do is they allow us to live more peacefully with this virus — to actually be able to not have it be so disruptive to society,” Michael Mina, an epidemiologist who’s been one of the most vocal proponents of rapid tests, told the Washington Post. These tests can make quarantines unnecessary, allowing us “to keep students in school, to keep businesses running and to stop the need for shutdowns, even amid outbreaks.”

The next generation of at-home tests

Up till now, at-home testing has been pretty much synonymous with antigen tests, such as BinaxNOW or QuickVue. Overall, these tests’ sensitivity tends to be in the range of 85 percent, meaning they miss about 15 percent of people who are infected. That said, they’re very good at detecting an infection when people have high viral loads, which is when they’re likeliest to infect others.

Molecular tests are considered the gold standard in Covid-19 testing. They take your sample and amplify the genetic material in it many times over, so if there’s even a tiny shred of virus in it, they will almost certainly detect it. Traditionally, the downside has been that you need a professional to swab you and a lab to process your results.

At-home molecular testing is starting to change that. This month, the health tech company Cue Health began selling directly to consumers a molecular test that can be performed entirely at home. You can buy it online, no prescription needed, and get lab-quality results without leaving home, according to the company. The Cue test shows results in line with lab PCR results 97.8 percent of the time, as verified in an independent study conducted by the Mayo Clinic.

And it’s quick, offering results in 20 minutes, similar to the wait time for antigen tests. There’s a catch, though: It’s not cheap. A three-pack of single-use tests will run you $225, and that’s not counting the reusable reader, which costs $250. At that price point, it’s far from ripe for equitable access. (For comparison, antigen tests are priced from about $10 to $40 per test.)

“We’re not priced like an antigen test, but we don’t perform like an antigen test,” said Clint Sever, Cue’s co-founder and chief product officer, adding that the test is used by the likes of Google, NASA, and the NBA. “It’s a breakthrough technology.”

Detect is another health tech company offering an at-home molecular test (the product will be available soon). This one will also come with a reusable hub and single-use individual tests. With the hub priced at $39 and each test at $49, Detect’s system will be more affordable than Cue’s, though still pricier than an antigen test. The Detect test is 97.3 percent accurate, similar to a PCR lab test, according to Axios. It returns results in one hour.

Both Cue’s and Detect’s tests have earned an emergency use authorization from the FDA, and both companies have their sights set on much more than just Covid-19 testing. With a bit of tweaking, their platforms should be able to test for other health issues, too.

Detect’s plan “is that you’ll be able to get a flu test or a Covid test or whatever you need, at home,” Owen Kaye-Kauderer, the company’s chief business officer, told Axios.

Cue envisions a future where its reader will be able to test you for everything from the flu and strep throat to chlamydia and gonorrhea. “Covid has basically accelerated the transition to virtual care services and connected diagnostics,” Sever told me.

The fundamental innovation here — giving your humble home the diagnostic capabilities of a professional lab — will likely become popular in many areas of health care over the next few years. That helps explain why companies like Cue and Detect are eager to get into the game, even though many experts say that as we approach springtime, Covid-19 will likely be entering the endemic phase: It’ll keep circulating in parts of the population, but its prevalence and impact will come down to relatively manageable levels, so it becomes more like the flu than a world-stopping disease.

“When we get to the point where transmission has slowed and we enter the endemic phase,” Sehgal said, “at-home testing becomes much less important.”

In the meantime, Wen recommends that each family keep a few at-home tests in the house. Don’t fret too much about whether they’re antigen or molecular; get what you can find and afford.

“This is a case of ‘don’t let the perfect be the enemy of the good,’” she said. “These tests can allow us to go from Covid-19 as a threat that feels almost existential to just another risk among all the risks we take into account every day. They can let us get back the normalcy we’re craving.”

Sigal Samuel

Source: At-home Covid tests are getting better. Stock up for winter holidays. – Vox

.

More Contents:

How Connected Life Sciences Devices Lead To Continuous Care

With connected medical devices, apps and data, life sciences organizations can bridge long-standing gaps in healthcare and deliver a more continuous care experience, says Brian Williams, Cognizant’s Chief Digital Officer for Life Sciences.

Global health systems have traditionally delivered services episodically, by focusing on acute, critical care rather than individual health and well-being. It should come as no surprise, then, that life sciences companies often deliver their solutions following that same model of care.

Sadly, this leads to gaps in data and service alignment, not to mention significant disconnects with the broader healthcare ecosystem. Consumer devices and wellness apps, for example, often exist within their own individual siloes — causing organizations to miss out on valuable data that could inform patient diagnosis, management and treatment.

This lack of orchestration produces sub-optimal outcomes at significant expense to providers, payers and patients alike. It is also at direct odds with patients’ increasing digital expectations when using medical devices and when taking drugs and therapies. Whether they are participating in a clinical trial, living with a chronic condition or recovering from a procedure, patients expect to be informed and cared for with seamless digital experiences on par with what they receive when shopping or banking online.

However, the emergence of integrated, connected devices, apps and data has opened new possibilities for treatments and clinical trials. This new level of connectivity helps bridge a longstanding gap in wellness: the disconnect between an individual’s everyday health behavior and their episodic healthcare. These experiences generate valuable data insights, creating new commercial opportunities and the promise of better patient outcomes.

The impact of life sciences connectivity

Drawing from our recent series on healthcare IoT, here are three stakeholder groups within the healthcare and life sciences ecosystem that stand to benefit greatly from this new level of connectivity and the more continuous, predictive and preventive care it enables.

  • Patients with chronic conditions. Chronic diseases are often accompanied by additional conditions, such as depression, that can impede effective treatment. Consequently, information about an individual’s behavioral health status has become increasingly important in treatment decisions, as has information about the individual’s relationships with the people around them.
  • Wearable IoT devices that monitor fitness and health conditions can pair with an ever-growing set of apps for health, wellness and nutrition monitoring. Over time, a baseline of physiological indicators such as an individual’s heart rate and blood pressure, as well as activity, diet and sleep patterns, will develop. When additional data from clinical encounters, including diagnostic imaging, lab tests, genomics, stress tests and physician notes, is integrated with that baseline, it increases the ability to predict how an individual may respond to any particular treatment.
  • Elderly patients. Quite often, the most effective tools for early detection of a developing condition in elderly patients are not implants or biometric monitors, but devices that monitor changes in activities of daily living (ADL).
  • For example, the onset of congestive heart failure can be detected through reduced use of the bed, as patients with trouble breathing when lying down switch to sleeping semi-upright in a recliner. Changes in toilet flushes, meanwhile, can detect a urinary tract infection or incipient dehydration. Moreover, while one in four Americans over 65 falls each year, only half tell their doctor.
  • Passive infrared motion detectors, pressure sensors in beds and chairs, sensors for CO2 concentration, sound (vibration) and video — anonymized as necessary for privacy — can all be used to first establish a baseline of normal variability, and then be applied to detect significant deviations from that baseline. This continuous and nearly invisible sensing can be surprisingly effective in assisting in care.
  • Hospital clinicians and support staff. Healthcare is increasingly a team enterprise — including not only physicians, nurses, allied health staff and technicians but also AI-enabled equipment. The point of care is also expanding, with shortened hospital stays and more care delivered in outpatient facilities and in-home settings.
  • Connected sensors enable every member of the team to access to real-time data relevant to their task. Smart hospitals with a real-time health system (RTHS) can leverage sensors to collect data widely, distill and analyze it — and then quickly distribute curated findings to users. When captured remotely, this eases the transition in care from the hospital to other settings, allowing a more continuous and participatory level of care that extends long past a patient’s physical stay in a healthcare facility.
  • An RTHS can improve operations, clinical tasks and patient experience. For example, providers that boost operational effectiveness typically rely on a wide range of IoT-enabled asset management solutions that locate mobile assets, monitor equipment operating conditions and track inventories of consumables, pharmaceuticals and medical devices. This optimizes equipment utilization, reduces waste, increases equipment uptime and ensures optimal inventories.
  • Once clinicians and support staff can view how long various steps take in their workflows, where delays occur and what patients experience as a result, they can then evolve solutions based on a combination of their intimate day-to-day knowledge and data on how that workflow interacts with or is used by other functions.

From episodic to continuous care

Too often, the life sciences industry has delivered a one-size-fits-all approach to clinical trials and patient care that may not represent real-life, individual situations — situations that require tailored engagement that wrap therapies and interventions in end-to-end, digital solutions.

This can and should change. Device connectivity and access to data are impacting every aspect of healthcare and life sciences, moving the industry away from acute, episodic care, to a system that is more participatory and predictive.

For example, a patient may be walking a mere 24 hours after a typical hip surgery and could be discharged from the hospital a day or two after the procedure. However, that episodic care experience belies a much longer recovery and rehabilitation period spanning weeks or months.While that care experience today takes place largely outside the purview of the orthopedic surgeon, better device connectivity can enable patient monitoring — and even patient services — to be extended well beyond the length of the initial hospital visit.

Rather than relying on spotty reporting from physical therapists or the patients themselves, an orthopedist can continuously and seamlessly track a patient’s progress, and then decide when and how to intervene if things aren’t going as expected. Zimmer’s mymobility application, which supports patient engagement and monitoring outside the hospital following surgery, is a good example of what this looks like in practice.

A fully orchestrated ecosystem

Sensors and instrumentation — and the hundreds of APIs that connect them — can provide accurate and timely data about many parameters of the human condition. When this is all properly orchestrated, we can better understand how diseases progress and how bodies respond to various interventions.

That’s the intent behind our alliance with Philips and its HealthSuite Digital Platform, which is built on AWS and designed to simplify and standardize device connectivity, data access, identity management, and structured and unstructured data management within a high-trust, HIPAA and GDPR-compliant environment.

We believe that life sciences companies can derive true value from this influx of new data. Not only can the resulting insights inform new services, drugs and therapies and inspire new models of continuous engagement; they can also improve adherence to treatment and patient health.

To learn more, visit the Life Sciences section of our website.

Brian is Cognizant’s Chief Digital Officer for Life Sciences and is responsible for designing digitally enabled solutions to facilitate care access and delivery. He is also the Global Life Sciences Consulting

Source: How Connected Life Sciences Devices Lead To Continuous Care

.

Related Contents:

M. Birkholz; A. Mai; C. Wenger; C. Meliani; R. Scholz (2016). “Technology modules from micro- and nano-electronics for the life sciences”. WIREs Nanomed. Nanobiotech. 8 (3): 355–377. doi:10.1002/wnan.1367. PMID 26391194

“What is Biomonitoring?” (PDF). American Chemistry Council. Archived from the origin(2005-04-08). Natural Fibers, Biopolymers, and Biocomposites. CRC Press. ISBN 978-0-203-50820-6.

National Human Genome Research Institute (2010-11-08). “FAQ About Genetic and Genomic Science”

Some Vaccinated Travelers Are Already Getting Covid-19 Booster Shots But Experts Say That May Be Counterproductive

Since January, all travelers must test negative for Covid-19 within 72 hours of entering the U.S. There are many reports in recent months of both vaccinated and unvaccinated travelers testing positive within the last three days of their trip.

This can completely upend re-entry plans because a positive test result means delaying a return to the U.S.. Travelers must get retested until they receive a negative test result and, in the meantime, they must remain in their destination at their own expense, often under quarantine or isolation orders.

To give themselves an extra insurance policy against becoming a breakthrough case, some fully vaccinated American travelers are finagling a third shot of the vaccine a few weeks before leaving on their trip — even though the U.S. Food and Drug Administration (FDA) has yet to give booster shots an official green light. In some cases, they are simply presenting themselves as unvaccinated at pharmacies or other vaccine providers in order to get another dose. Others are getting a booster with the blessing of their doctors.

“People are acting in their own self-interest, and that doesn’t shock me,” said Dr. Kavita Patel, a primary care physician in Washington, D.C., who served as an advisor on health policy in the Obama administration.

“It’s unfortunate, because there remains no evidence that if you’re under 65 years old and otherwise healthy, that you need a third shot right now,” said Dr. Vin Gupta, a pulmonary critical-care physician and an affiliate assistant professor at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. “There needs to be guardrails here. We need to understand what three doses mean. Are we protected for five years or just another eight months? There are lots of open questions.”

The Biden administration has urged the FDA to release a booster rollout plan as soon as possible, given that some Americans, including first responders and immunocompromised people, received their initial doses in 2020 and officials want the most vulnerable people to be at the front of the line for boosters.

The FDA is currently evaluating when a wider swath of vaccinated Americans should begin receiving Covid-19 booster shots, which is likely to be either six or eight months after completing their initial doses. “The administration recently announced a plan to prepare for additional Covid-19 vaccine doses, or ‘boosters,’ this fall, and a key part of that plan is FDA completing an independent evaluation and determination of the safety and effectiveness of these additional vaccine doses,” said the agency in a statement.

Pending FDA approval, booster doses might begin rolling out to eligible Americans as early as this month, said U.S. Surgeon General Dr. Vivek Murthy on a call yesterday that was hosted by the U.S. Health and Human Services Covid-19 Community Corps.

It’s important for individuals to adhere to the FDA’s recommended timing of a third shot, said Dr. Patel. Just as with any other three-shot vaccine series, the intervals between shots will be gauged to give people robust immunity for a longer period of time.

“That’s actually consistent with what we do with other vaccines. Think of the timing of any pediatric vaccine or the human papillomavirus vaccine,” said Dr. Patel. “What I tell patients is that there’s actually a downside from getting a booster too early. They could be potentially harming themselves six to 12 months down the line. I mean, Covid is not going away.”

While Dr. Patel thinks “it’s inevitable” that everyone will eventually need another shot, “there’s unfortunately a perception that in order to go on a trip and avoid getting sick or avoid potential additional costs, people think that a booster is going to be what they need to do to stay protected. I think a lot of people are just thinking, ‘Well, if two is better than one and three is better than two, at some point, I’ll get four.’ And that’s a very dangerous assumption.”

In other words, instead of rushing to get a third shot before a planned trip, it makes more sense to stick to the optimal timing for a booster shot, then plan future trips accordingly.

Follow me on LinkedIn. Check out my website. Send me a secure tip.

I watch trends in travel. Prior to working at Forbes, I was a longtime freelancer who contributed hundreds of articles to Conde Nast Traveler, CNN Travel, Travel + Leisure, Afar, Reader’s Digest, TripSavvy, Parade, NBCNews.com and scores of other outlets. Follow me on Instagram (@suzannekelleher) and Flipboard (@SRKelleher).

Source: Some Vaccinated Travelers Are Already Getting Covid-19 Booster Shots—But Experts Say That May Be Counterproductive

.

Related Contents:

Hepatitis B and the Need for a Booster Dose

Top 20 Questions about Vaccination

Efficacy of inactivated poliovirus vaccine in India

Pharmacological management of tetanus: an evidence-based review

Pertussis | Whooping Cough | Complications | CDC

Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

Everything you need to know about the WTO’s COVID-19 vaccine patent proposal

The complexity and cost of vaccine manufacturing – An overview

Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply

Safety of vaccines used for routine immunization of U.S. children: a systematic review

Australian scientists develop ‘needle-free’ vaccination

Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky’s disease virus by a competitive enzyme immunoassay

A guide to vaccinology: from basic principles to new developments

%d bloggers like this: